For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
To determine if adding pembrolizumab to the standard treatment for triple negative breast cancer, decreases the risk of the cancer returning (after receiving standard chemotherapy and/or radiation).
DiagnosisStage II/III Triple Negative Breast Cancer
Patients must have had chemotherapy followed by surgery.
At least 1 cm of residual tumor tissue, or any residual positive lymph nodes, must be remaining at surgery.
Radiation (if applicable) may be done before or during study.
Patients must sign an approved informed consent and authorization
- Pembrolizumab (Keytruda)
- Quality of Life questionnaires
Patients will be followed every 6 months until 5 years from start of study, then every year until 10 years from start of study.
For more information, visit the ClinicalTrials.gov.